New EMA report on paliperidone 3-month injections: taking clinical and policy decisions without an adequate evidence base

Safety and tolerability of long-acting injectable versus oral antipsychotics: A meta-analysis of randomized controlled studies comparing the same antipsychotics

(2016) Fuminari Misawa et al.   SCHIZOPHRENIA RESEARCH

Comparative effectiveness of long-acting antipsychotics: issues and challenges from a pragmatic randomised study

(2015) G. Ostuzzi et al.   Epidemiology and Psychiatric Sciences

Expanding Therapy With Long-Acting Antipsychotic Medication in Patients With Schizophrenia

(2015) William T. Carpenter et al.   JAMA Psychiatry

Efficacy and Safety of the 3-Month Formulation of Paliperidone Palmitate vs Placebo for Relapse Prevention of Schizophrenia

(2015) Joris Berwaerts et al.   JAMA Psychiatry

Should non-inferiority drug trials be banned altogether?

(2013) Grace Wangge et al.   DRUG DISCOVERY TODAY

Regulatory science in Europe: the case of schizophrenia trials

(2013) Corrado Barbui et al.   LANCET

Regulatory Scientific Advice on Non-Inferiority Drug Trials

(2013) Grace Wangge et al.   PLoS One

Long-Acting Injectable vs Oral Antipsychotics for Relapse Prevention in Schizophrenia: A Meta-Analysis of Randomized Trials

(2012) T. Kishimoto et al.   SCHIZOPHRENIA BULLETIN

Oral versus depot antipsychotic drugs for schizophrenia—A critical systematic review and meta-analysis of randomised long-term trials

(2011) Claudia Leucht et al.   SCHIZOPHRENIA RESEARCH

Through the looking glass: understanding non-inferiority

(2011) Jennifer Schumi et al.   Trials